Historical Valuation
Medifast Inc (MED) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.32 is considered Undervalued compared with the five-year average of 10.99. The fair price of Medifast Inc (MED) is between 15.13 to 46.10 according to relative valuation methord. Compared to the current price of 11.42 USD , Medifast Inc is Undervalued By 24.53%.
Relative Value
Fair Zone
15.13-46.10
Current Price：11.42
24.53%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Medifast Inc (MED) has a current Price-to-Book (P/B) ratio of 0.50. Compared to its 3-year average P/B ratio of 2.54 , the current P/B ratio is approximately -80.38% higher. Relative to its 5-year average P/B ratio of 6.72, the current P/B ratio is about -92.59% higher. Medifast Inc (MED) has a Forward Free Cash Flow (FCF) yield of approximately 0.60%. Compared to its 3-year average FCF yield of 17.55%, the current FCF yield is approximately -96.56% lower. Relative to its 5-year average FCF yield of 12.40% , the current FCF yield is about -95.12% lower.
P/B
Median3y
2.54
Median5y
6.72
FCF Yield
Median3y
17.55
Median5y
12.40
Competitors Valuation Multiple
AI Analysis for MED
The average P/S ratio for MED competitors is 0.43, providing a benchmark for relative valuation. Medifast Inc Corp (MED.N) exhibits a P/S ratio of 0.32, which is -25.23% above the industry average. Given its robust revenue growth of -36.21%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for MED
1Y
3Y
5Y
Market capitalization of MED increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of MED in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is MED currently overvalued or undervalued?
Medifast Inc (MED) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.32 is considered Undervalued compared with the five-year average of 10.99. The fair price of Medifast Inc (MED) is between 15.13 to 46.10 according to relative valuation methord. Compared to the current price of 11.42 USD , Medifast Inc is Undervalued By 24.53% .
What is Medifast Inc (MED) fair value?
MED's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Medifast Inc (MED) is between 15.13 to 46.10 according to relative valuation methord.
How does MED's valuation metrics compare to the industry average?
The average P/S ratio for MED's competitors is 0.43, providing a benchmark for relative valuation. Medifast Inc Corp (MED) exhibits a P/S ratio of 0.32, which is -25.23% above the industry average. Given its robust revenue growth of -36.21%, this premium appears unsustainable.
What is the current P/B ratio for Medifast Inc (MED) as of Jan 10 2026?
As of Jan 10 2026, Medifast Inc (MED) has a P/B ratio of 0.50. This indicates that the market values MED at 0.50 times its book value.
What is the current FCF Yield for Medifast Inc (MED) as of Jan 10 2026?
As of Jan 10 2026, Medifast Inc (MED) has a FCF Yield of 0.60%. This means that for every dollar of Medifast Inc’s market capitalization, the company generates 0.60 cents in free cash flow.
What is the current Forward P/E ratio for Medifast Inc (MED) as of Jan 10 2026?
As of Jan 10 2026, Medifast Inc (MED) has a Forward P/E ratio of -6.15. This means the market is willing to pay $-6.15 for every dollar of Medifast Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Medifast Inc (MED) as of Jan 10 2026?
As of Jan 10 2026, Medifast Inc (MED) has a Forward P/S ratio of 0.32. This means the market is valuing MED at $0.32 for every dollar of expected revenue over the next 12 months.